Stockreport

Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Advaxis, Inc.  (ADXS) 
Last advaxis, inc. earnings: 9/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.advaxis.com
PDF -ADXS-NEO is being evaluated in a Phase 1 clinical trial in various cancers -First patient dosed is being treated for NSCLC PRINCETON, [Read more]